Bioatla announces fourth quarter and full year 2021 financial results

San diego, march 1, 2022 /prnewswire/ -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics, today announces its financial results for the fourth quarter and full year december 31, 2021, and provides an update on product pipeline developments. "bioatla made significant progress in 2021 by advancing the potentially registration-enabling phase 2 clinical trials for our two lead cab product candidates as well as our other preclinical and pipeline programs.
BCAB Ratings Summary
BCAB Quant Ranking